Incyte (INCY)
(Delayed Data from NSDQ)
$76.13 USD
+2.01 (2.71%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$76.13 USD
+2.01 (2.71%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $75.81 -0.32 (-0.42%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Incyte and Calithera Enter into Deal for Oncology Candidate
by Zacks Equity Research
Incyte Corporation (INCY) and Calithera Biosciences, Inc. (CALA) entered into a global collaboration and license agreement for research, development and commercialization of Calithera's CB-1158 in hematology and oncology.
Calithera Biosciences (CALA) In Focus: Stock Jumps 46.7%
by Zacks Equity Research
Calithera Biosciences, Inc. (CALA) moved big last session, as its shares jumped almost 47% on the day.
5 Toxic Stocks to Dump or Play Short Now
by Zacks Equity Research
Higher price of the toxic stocks can be attributed to either an irrational exuberance associated with them or some serious fundamental lacuna.
Lilly-Incyte Rheumatoid Arthritis Drug PDUFA Date Extended
by Zacks Equity Research
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) announced that the FDA has extended the time to review the company's NDA for baricitinib for the treatment of rheumatoid arthritis (RA).
4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal
by Arpita Dutt
Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?
Incyte/Merck to Start More Epacadostat-Keytruda Studies
by Zacks Equity Research
Incyte (INCY) and Merck (MRK) announced that they have decided to initiate additional pivotal studies on epacadostat, in combination with Merck's Keytruda.
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Bluerock Residential Growth REIT, Cal-Maine Foods, Incyte, Eli Lilly and Synergy Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
Incyte Treats First Patient in Phase II GVHD Study on Jakafi
by Zacks Equity Research
Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.
Two Key FDA Decisions to Watch Out for in January 2017
by Arpita Dutt
Incyte (INCY) and Synergy (SGYP) have important regulatory events coming up this month.
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Celgene, Incyte, Eli Lilly, Regeneron Pharmaceuticals and Ophthotech
Incyte/Merus Ink Collaboration for Bispecific Antibodies
by Zacks Equity Research
Incyte (INCY) entered into an agreement with Merus (MRUS) to discover and develop bispecific antibodies using the latter's proprietary Biclonics technology platform.
Incyte/Lilly Olumiant Wins CHMP Nod for Rheumatoid Arthritis
by Zacks Equity Research
Incyte (INCY) and Eli Lilly (LLY) announced that the EMA's CHMP has issued a positive opinion for the approval of Olumiant (baricitinib).
Incyte Jakafi Positive in Pooled Analysis of Five-Year Data
by Zacks Equity Research
Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.
Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors
by Zacks Equity Research
Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.
New Strong Buy Stocks for October 11th
by Indradip Ghosh
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
New Strong Buy Stocks for August 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include OPHT, XNPT, OSUR, INCY and AGIO.